Table 1: Larger studies in first-line treatment of CLL patients.

TrialRegiments CROROS (months/% survivor at time)Median PFS (months)

Dighiero et al. [14]Chlorambucil 29345%49%NDND
Eichhorst et al. [15]Chlorambucil100051%6418
versus fludarabine937%72%4619
Rai et al. [16]Chlorambucil1814%37%5614
versus fludarabine17020%63%6620
Eichhorst et al. [17]Fludarabine1647%83%81% at 3 y20
versus FC16424%94%80% at 3 y48
Robak et al. [18]CC19247%88%62.4% at 4 y28
versus FC20346%82%60.6% at 4 y27
Robak et al. [19]Cladribine17421%78%4527.2
versus CC17129%83%4822.4
versus CMC16336%80%4625.6
Hallek et al. [20]FC40922%88%ND52
versus rituximab-FC40844%95%ND53
Kay et al. [21]PCR6441%91%ND33
Knauf et al. [22]Chlorambucil1572%31%ND8.3
versus bendamustine16231%63%ND21.6
Thornton et al. [23]HDMP250%77%ND12
Hillmen et al. [24]Alemtuzumab14924%83%ND14.6
versus chlorambucil1482%55%ND11.7

: number of patients in the trial, CR: complete response, PR: partial response, OR: overall response, OS: overall survival, PFS: progression-free survival, ND: no data, FC: fludarabine and cyclophosphamide CC: cladribine and cyclophosphamide, CMC: cladribine, cyclophosphamide, and mitoxantrone, PCR: pentostatin, cyclophosphamide, and rituximab, HDMP: high-dose methylprednisolone.